Hazard ratios can be approximated by data extracted from published Kaplan–Meier
curves. Recently, this curve approach has been extended beyond hazard-ratio
approximation with the capability of constructing time-to-event data at the
individual level. In this article, we introduce a command,
ipdfc, to implement the reconstruction method to
convert Kaplan–Meier curves to time-to-event data. We give examples to
illustrate how to use the command.
BarlowR. E.,
BartholomewD. J., BremnerJ. M., and BrunkH. D.1972. Statistical Inference Under Order Restrictions:
Theory and Application of Isotonic Regression.New York:
Wiley.
2.
BonnerJ. A., HarariP. M., GiraltJ., AzarniaN., ShinD. M., CohenR. B., JonesC. U., SurR., RabenD., JassemJ., OveR., KiesM. S., BaselgaJ., YoussoufianH., AmellalN., RowinskyE. K., and AngK. K.2006. Radiotherapy plus cetuximab for squamous-cell
carcinoma of the head and neck. New England Journal
of Medicine354: 567–578.
3.
DeeksJ. J., HigginsJ. P. T., and
AltmanD. G.2008. Analysing data and undertaking
meta-analyses. In Cochrane Handbook for Systematic
Reviews of Interventions, ed. HigginsJ. P. T., and
GreenS., 243–296.
Chichester, UK:
Wiley.
4.
FoxK. M.2003. Efficacy of perindopril in reduction of
cardiovascular events among patients with stable coronary artery disease:
Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA
study). Lancet362: 782–788.
5.
GuyotP., AdesA. E., OuwensM. J. N. M., and
WeltonN. J.2012. Enhanced secondary analysis of survival data:
Reconstructing the data from published Kaplan–Meier survival
curves. BMC Medical Research Methodology12: 9.
6.
ParmarM. K. B., TorriV., and StewartL.1989. Extracting summary statistics to perform
meta-analyses of the published literature for survival
endpoints. Statistics in Medicine17: 2815–2834.
7.
PerrenT. J., SwartA. M., PfistererJ., LedermannJ. A.,
Pujade-LauraineE., KristensenG., CareyM. S., BealeP., CervantesA., KurzederC., du BoisA., SehouliJ., KimmigR., StähleA., CollinsonF., EssapenS., GourleyC., LortholaryA., SelleF., MirzaM. R., LeminenA., PlanteM., StarkD., QianW., ParmarM. K. B., and OzaA. M.2011. A phase 3 trial of bevacizumab in ovarian
cancer. New England Journal of Medicine365: 2484–2496.
8.
van PuttenW., and RoystonP.2017. irax: Stata module to perform isotonic regression
analysis. Statistical Software Components S458406,
Department of Economics, Boston College.
https://ideas.repec.org/c/boc/bocode/s458406.html.
9.
RoystonP., and ParmarM. K. B.2011. The use of restricted mean survival time to
estimate the treatment effect in randomized clinical trials when the
proportional hazards assumption is in doubt.
Statistics in Medicine30: 2409–2421.
10.
TierneyJ. F., StewartL. A., GhersiD., BurdettS., and SydesM. R.2007. Practical methods for incorporating summary
time-to-event data into meta-analysis.
Trials8: 16.
11.
WeiY., RoystonP., TierneyJ. F., and ParmarM. K. B.2015. Meta-analysis of time-to-event outcomes from
randomized trials using restricted mean survival time: Application to
individual participant data. Statistics in
Medicine34: 2881–2898.
12.
WilliamsonP. R., SmithC. T., HuttonJ. L., and MarsonA. G.2002. Aggregate data meta-analysis with
time-to-event outcomes. Statistics in
Medicine21: 3337–3351.
